Incorporating Voluntary Patient Preference Information Over the Total Product Life Cycle; Guidance for Industry, Food and Drug Administration Staff, and Other Interested Parties; Availability
Published Date: 3/30/2026
Notice
Summary
The FDA just dropped new guidance to help drug and device makers include patient preferences when developing and reviewing medical products. This means patients’ voices will play a bigger role from early testing to final approval, making treatments more in tune with what people really want. Companies should start using this advice now to improve their products and speed up FDA decisions, potentially saving time and money.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in